References

Adams, C. P., and V. V. Brantner. 2006. Estimating the cost of new drug development: Is it really $802 million? Health Affairs 25(2):420-428. http://content.healthaffairs.org/content/25/2/420.full.html (accessed January 31, 2012).

AHRQ (Agency for Healthcare Research and Quality). 2011. AHRQ at a glance. http://www.ahrq.gov/about/ataglance.htm (accessed November 11, 2011).

Bonham, A. C., R. M. Califf, E. K. Gallin, and M. S. Lauer. 2012. Developing a robust clinical trials workforce. Discussion Paper, Institute of Medicine, Washington, DC.

Califf, R. M., G. L. Filerman, R. K. Murray, and M. Rosenblatt. 2012. The clinical trials enterprise in the United States: A call for disruptive innovation. Discussion Paper, Institute of Medicine, Washington, DC.

CenterWatch. 2011. Proposed Common Rule updates focus on consent, definitions, streamlined IRB review, data protection. October 31. http://centerwatch.com/news-online/article/2443/proposed-common-rule-updates-focus-on-consent-definitions-streamlined-irb-review-data-protection (accessed January 11, 2012).

CERN (European Organization for Nuclear Research). 2011. ATLAS and CMS experiments present Higgs search status. http://public.web.cern.ch/public/ (accessed December 18, 2011).

DeVol, R. C., A. Bedroussian, and B. Yeo. 2011. The global biomedical industry: Preserving U.S. leadership. http://www.milkeninstitute.org/pdf/CASMIFullReport.pdf (accessed February 9, 2012).

Deyell, M.W., C. E. Buller, L. H. Miller, T. Y. Wang, D. Dai, G. A. Lamas, V. S. Srinivas, and J. S. Hochman. 2011. Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. Archives of Internal Medicine 171(18):1636-1643.

Dzau, V. J., D. C. Ackerly P. Sutton-Wallace, M. H. Merson, R. S. Williams, K. R. Krishnan, R. C. Taber, and R. M. Califf. 2010. The role of academic health science systems in the transformation of medicine. Lancet 375:949-953.

Eisenberg, P., P. Kaufmann, E. V. Sigal, and J. Woodcock. 2012. Developing a clinical trials infrastructure. Discussion Paper, Institute of Medicine, Washington, DC.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 81
References Adams, C. P., and V. V. Brantner. 2006. Estimating the cost of new drug development: Is it really $802 million? Health Affairs 25(2):420-428. http://content.healthaffairs.org/ content/25/2/420.full.html (accessed January 31, 2012). AHRQ (Agency for Healthcare Research and Quality). 2011. AHRQ at a glance. http://www. ahrq.gov/about/ataglance.htm (accessed November 11, 2011). Bonham, A. C., R. M. Califf, E. K. Gallin, and M. S. Lauer. 2012. Developing a robust clinical trials workforce. Discussion Paper, Institute of Medicine, Washington, DC. Califf, R. M., G. L. Filerman, R. K. Murray, and M. Rosenblatt. 2012. The clinical trials enter- prise in the United States: A call for disruptive innovation. Discussion Paper, Institute of Medicine, Washington, DC. CenterWatch. 2011. Proposed Common Rule updates focus on consent, definitions, streamlined IRB review, data protection. October 31. http://centerwatch.com/news-online/article/2443/ proposed-common-rule-updates-focus-on-consent-definitions-streamlined-irb-review- data-protection (accessed January 11, 2012). CERN (European Organization for Nuclear Research). 2011. ATLAS and CMS experiments present Higgs search status. http://public.web.cern.ch/public/ (accessed December 18, 2011). DeVol, R. C., A. Bedroussian, and B. Yeo. 2011. The global biomedical industry: Preserving U.S. leadership. http://www.milkeninstitute.org/pdf/CASMIFullReport.pdf (accessed February 9, 2012). Deyell, M.W., C. E. Buller, L. H. Miller, T. Y. Wang, D. Dai, G. A. Lamas, V. S. Srinivas, and J. S. Hochman. 2011. Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. Archives of Internal Medicine 171(18):1636-1643. Dzau, V. J., D. C. Ackerly, P. Sutton-Wallace, M. H. Merson, R. S. Williams, K. R. Krishnan, R. C. Taber, and R. M. Califf. 2010. The role of academic health science systems in the transformation of medicine. Lancet 375:949-953. Eisenberg, P., P. Kaufmann, E. V. Sigal, and J. Woodcock. 2012. Developing a clinical trials infrastructure. Discussion Paper, Institute of Medicine, Washington, DC. 81

OCR for page 81
82 ENVISIONING A TRANSFORMED CLINICAL TRIALS ENTERPRISE Executive Office of the President, President’s Council of Advisors on Science and Technol- ogy. 2010. Realizing the full potential of health information technology to improve healthcare for Americans: The path forward. Report to the President. Washington, DC: The White House. http://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-health-it-report. pdf (accessed November 10, 2011). FDA (Food and Drug Administration). 2010. Advancing regulatory science for public health. http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm228131. htm (accessed January 23, 2012). Gallin, J. I. 2011. Sustaining institutional support and patient engagement in clinical trials: Models and messages from the NIH Clinical Center. Speaker presentation at the IOM Workshop on Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020, November 7, Washington, DC. HHS (Department of Health and Human Services). 2011. Advanced Notice of Proposed Rule- making: Human subjects protections update. http://www.hhs.gov/ohrp/humansubjects/ index.html (accessed December 12, 2011). Hochman, J. S., G. A. Lamas, C. E. Buller, V. Dzavik, H. R. Reynolds, S. J. Abramsky, S. Forman, W. Ruzyllo, A. P. Maggioni, H. White, Z. Sadowski, A. C. Carvalho, J. M. Rankin, J. P. Renkin, P. G. Steg, A. M. Mascette, G. Sopko, M. E. Pfisterer, J. Leor, V. Fridrich, D. B. Mark, and G. L. Knatterud. 2006. Coronary intervention for persistent occlusion after myocardial infarction. New England Journal of Medicine 355(23):2395-2407. i2b2. 2011. Informatics for integrating biology and the bedside. https://www.i2b2.org/ (ac- cessed December 2, 2011). IOM (Institute of Medicine). 2001. Crossing the quality chasm: A new health system for the 21st century. Washington, DC: National Academy Press. IOM. 2004. Health literacy: A prescription to end confusion. Washington, DC: The National Academies Press. IOM. 2007. The learning healthcare system. Workshop summary. Washington, DC: The National Academies Press. IOM. 2009. Initial national priorities for comparative effectiveness research. Washington, DC: The National Academies Press. IOM. 2010a. Transforming clinical research in the United States: Challenges and opportunities. Workshop summary. Washington, DC: The National Academies Press. IOM. 2010b. The healthcare imperative: Lowering costs and improving outcomes. Workshop sum- mary. Washington, DC: The National Academies Press. IOM. 2011a. Engineering a learning healthcare system: A look at the future. Workshop summary. Washington, DC: The National Academies Press. IOM. 2011b. Learning what works: Infrastructure required for comparative effectiveness research. Workshop summary. Washington, DC: The National Academies Press. IOM. 2011c. Innovations in health literacy research. Workshop summary. Washington, DC: The National Academies Press. IOM. 2012a. Public engagement and clinical trials: New models and disruptive technologies. Work- shop summary. Washington, DC: The National Academies Press. IOM. 2012b. Strengthening a workforce for innovative regulatory science in therapeutics develop - ment. Workshop summary. Washington, DC: The National Academies Press. Jolly, M. K. 2011. PACeR: The Partnership to Accelerate Clinical electronic Research—improves predictive success. Speaker presentation at the IOM workshop on Envisioning a Trans- formed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020, November 8, 2011, Washington, DC. Kapowich, J. M. 2010. Oregon’s test of value-based insurance design in coverage for state workers. Health Affairs 29(11):2028-2032. Kocher, R., and N. R. Sahni. 2011. Rethinking health care labor. New England Journal of Medi- cine 365(15):1370-1372.

OCR for page 81
83 REFERENCES Kolodziej, M. A. 2011. The community oncologist: Part of the solution. Journal of the National Comprehensive Cancer Network 9:345-347. Kost, R. G., L. M. Lee, J. Yessis, B. S. Coller, D. K. Henderson, and The Research Participant Perception Survey Focus Group Subcommittee. 2011. Assessing research participants’ perceptions of their clinical research experiences. Clinical and Translational Science 4(6):403-413. Kramer, J. M., and K. A. Schulman. 2011. Transforming the economics of clinical trials. Speaker presentation at the Institute of Medicine Workshop on Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020, No - vember 7-8, Washington, DC. Kramer, J. M., and K. A. Schulman. 2012. Transforming the economics of clinical trials. Discus- sion Paper, Institute of Medicine, Washington, DC. Law, M. R., Y. Kawasumi, and S. G. Morgan. 2011. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on clinicaltrials.gov. Health Affairs 30(12):2338-2345. Lee, D. H., and O. Vielemeyer. 2011. Analysis of overall level of evidence behind Infectious Disease Society of America practice guidelines. Annals of Internal Medicine 171:18-22. Lilford, R. J., and J. Jackson. 1995. Equipoise and the ethics of randomization. Journal of the Royal Society of Medicine 88:552-559. Mackenzie, I. S., L. Wei, D. Rutherford, E. A. Findlay, W. Saywood, M. K. Campbell, and T. M. MacDonald. 2010. Promoting public awareness of randomised clinical trials using the media: The “Get Randomised” campaign. Journal of Clinical Pharmacology 69(2):128-135. Mansell, P. 2011. Pfizer announces “virtual” clinical trial pilot in U.S. PharmaTimes, June 9. http://www.pharmatimes.com/Article/11-06-09/Pfizer_announces_virtual_clinical_ trial_pilot_in_US.aspx (accessed December 8, 2011). National Marfan Foundation. 2011. Atenolol versus losartan clinical trial. http://www.marfan. org/marfan/2408/Atenolol-vs.-Losartan-Clinical-Trial (accessed December 5, 2011). NIH (National Institutes of Health), Division of Program Coordination, Planning and Strategic Initiatives. 2011. The NIH Common Fund. http://commonfund.nih.gov/ researchteams/index.aspx (accessed November 18, 2011). NIH, Scientific Management Review Board. 2010. Report on the NIH Clinical Center. http:// smrb.od.nih.gov/ (accessed April 10, 2012). O’Connor, C. M., R. C. Starling, A. F. Hernandez, P. W. Armstrong, K. Dickstein, V. Hasselblad, G. M. Heizer, M. Komajda, B. M. Massie, J. J. V. McMurray, M. S. Nieminen, C. J. Reist, J. L. Rouleau, K. Swedberg, K. F. Adams, S. D. Anker, D. Atar, A. Battler, R. Botero, N. R. Bohidar, J. Butler, N. Clausell, R. Corbalán, M. R. Costanzo, U. Dahlstrom, L. I. Deckelbaum, R. Diaz, M. E. Dunlap, J. A. Ezekowitz, D. Feldman, G. M. Felker, G. C. Fonarow, D. Gennevois, S. S. Gottlieb, J. A. Hill, J. E. Hollander, J. G. Howlett, M. P. Hudson, R. D. Kociol, H. Krum, A. Laucevicius, W. C. Levy, G. F. Méndez, M. Metra, S. Mittal, B.-H. Oh, N. L. Pereira, P. Ponikowski, W. H. W. Tang, S. Tanomsup, J. R. Teerlink, F. Triposkiadis, R. W. Troughton, A. A. Voors, D. J. Whellan, F. Zannad, and R. M. Califf. 2011. Effect of nesiritide in patients with acute decompensated heart failure. New England Journal of Medicine 365(1):32-43. Platt, R., Takvorian S.U., Septimus E., Hickok J., Moody J., Perlin J., Jernigan J. A., Kleinman K., Huang S. S. 2010. Cluster randomized trials in comparative effectiveness research: Randomizing hospitals to test methods for prevention of healthcare-associated infec - tions. Medical Care 48(6):S52-S57. Platt, R., R. M. Carnahan, J. S. Brown, E. Chrischilles, L. H. Curtis, S. Hennessy, J. C. Nelson, J. A. Racoosin, M. Robb, S. Schneeweiss, S. Toh, and M. G. Weiner. 2012. The U.S. Food and Drug Administration’s Mini-Sentinel program: Status and direction. Pharmacoepidemiology and Drug Safety 21(S1):1-8.

OCR for page 81
84 ENVISIONING A TRANSFORMED CLINICAL TRIALS ENTERPRISE Pollack, A. 2011. FDA approves drug for lupus, an innovation after 50 years. New York Times, March 9. http://www.nytimes.com/2011/03/10/health/10drug.html (accessed December 4, 2011). Ramsey, B. W., J. Davies, N. G. McElvaney, E. Tullis, S. C. Bell, P. Drevinek, M. Griese, E. F. McKone, C. E. Wainwright, M. W. Konstan, R. Moss, F. Ratjen, I. Sermet-Gaudelus, S. M. Rowe, Q. Dong, S. Rodriguez, K. Yen, C. Ordonez, and J. S. Elborn. 2011. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine 365(18):1663-1672. Research!America. 2007. Americans expect medical breakthroughs. http://www.researchamerica. org/uploads/poll.report.2007.transforminghealth.pdf (accessed December 4, 2011). Rudd, R. E., J. E. Anderson, S. Oppenheimer, and C. Nath. 2007. Health literacy: An update of public health and medical literature. In Review of Adult Learning and Literacy, Vol. 7, edited by J. P. Comings, B. Garner, and C. Smith. Mahwah, NJ: Lawrence Erlbaum Associates. Pp. 175-204. Schaefer, G. O., E. J. Emanuel, and A. Wertheimer. 2009. The obligation to participate in biomedical research. Journal of the American Medical Association 302(1):67-72. Sung, N. S., W. F. Crowley, M. Genel, P. Salber, L. Sandy, L. M. Sherwood, S. B. Johnson, V. Catanese, H. Tilson, K. Getz, E. L. Larson, D. Scheinberg, E. A. Reece, H. Slavkin, A. Dobs, J. Grebb, R. A. Martinez, A. Korn, and D. Rimoin. 2003. Central challenges fac - ing the national clinical research enterprise. Journal of the American Medical Association 289(10):1278-1287. Topol, E.J. 2005. Nesiritide—not verified. New England Journal of Medicine 353(2):113-116. Tricoci, P., J. M. Allen, J. M. Kramer, R. M. Califf, and S. C. Smith, Jr. 2009. Scientific evidence underlying the ACC/AHA clinical practice guidelines. Journal of the American Medical Association 301:967-974. Tufts Center for the Study of Drug Development. 2007. Impact report: Notable gender and racial disparities exist among clinical investigators. November/December, 9(6). http://csdd. tufts.edu/files/uploads/08_-_nov._5,_2007_-_principal_investigators.pdf (accessed January 23, 2011). Varmus, H. and E. Harlow. 2012. Provocative questions in cancer research. Nature 481:436-437. http://www.nature.com/nature/journal/v481/n7382/full/481436a.html (accessed Janu- ary 30, 2012). Vastag, B., and J. Achenbach. 2011. Scientists close in on linchpin of physics, the “God par- ticle.” Washington Post, December 12. http://www.washingtonpost.com/national/ health-science/scientists-close-in-on-linchpin-of-physics-the-god-particle/2011/12/12/ gIQAmk2cqO_story.html (accessed December 18, 2011). Vincent, G. K., and V. A. Velkoff. 2010. The next four decades: The older population in the United States: 2010 to 2050. Current Population Reports. Washington, DC: U.S. Census Bureau. Wallentin, L., R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. W. Mahaffey, B. M. Scirica, A. Skene, P. G. Steg, R. F. Storey, and R. A. Harrington. 2009. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine 361(11):1045-1057. Wood, A. 2011. Envisioning CTE in the health care system of 2020. Speaker presentation at the Institute of Medicine Workshop on Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020, November 7-8, Washington, DC. Yu, P. 2011. The learning health system. Speaker presentation at the IOM workshop on Envi- sioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020, November 7, 2011, Washington, DC.